Monitor upcoming Q2 earnings for profitability recovery as guided, and track early Lifyorli sales trajectory. Insider sales are minor and do not warrant action, but any acceleration in selling by C-suite would be a watch item.
Price Chart
Executive Summary
Corcept Therapeutics' CEO and CDO sold $3.04M in open-market shares within a week of the Q1 earnings release. The trades represent only ~0.05% of market cap and are likely routine portfolio management, not a bearish signal. Q1 revenue grew 4.9% YoY to $164.9M, but the company reported a net loss of $31.8M vs net income of $20.5M in the prior year, driven by increased spending on the Lifyorli launch.
Key Financial Metrics
Key Facts
- CEO Belanoff sold 40,000 shares at ~$50.10 for $2.00M on May 1, 2026.
- CDO Guyer sold 20,000 shares at ~$51.83 for $1.04M on May 5, 2026 (also exercised options with no cash impact).
- Total insider sales of $3.04M represent ~0.054% of $5.6B market cap.
- Q1 2026 revenue rose 4.9% YoY to $164.9M; net loss of $31.8M vs net income of $20.5M in Q1 2025.
- 2026 revenue guidance raised to $950M-$1,050M; Lifyorli (relacorilant) approved by FDA for ovarian cancer in March 2026.
Financial Impact
Insider selling of $3.04M is negligible relative to $5.6B market cap.
Risk Factors
- Delays in relacorilant NDA for Cushing's syndrome or regulatory setbacks.
- Competition in ovarian cancer and Cushing's syndrome markets.
- Failure to return to profitability as guided in Q2 2026.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-CORT-1778185862573 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 28, 2026 5w ago | Insider Cluster | $113.88 $115.63 | ▲ +1.54% | ▲ +1.28% | $116.49 (+2.29%) |
Aug 28, 2026 5w ago | Insider Cluster | $113.88 $116.10 | ▲ +1.95% | ▲ +1.44% | $116.49 (+2.29%) |
Aug 27, 2026 5w ago | Insider Cluster | $116.93 $117.00 | ▲ +0.06% | ▲ +0.16% | $116.49 (−0.38%) |
Aug 20, 2026 6w ago | Insider Cluster | $121.05 $114.86 | ▼ −5.11% | ▼ −5.11% | $116.49 (−3.77%) |
Aug 18, 2026 6w ago | Insider Cluster | $118.10 $111.85 | ▲ +5.29% | ▲ +4.30% | $116.49 (+1.36%) |
Aug 12, 2026 7w ago | Insider Cluster | $112.18 $114.92 | ▲ +2.44% | ▲ +4.34% | $116.49 (+3.84%) |
Aug 12, 2026 7w ago | Insider Cluster | $112.18 $114.92 | ▲ +2.44% | ▲ +4.34% | $116.49 (+3.84%) |
Aug 6, 2026 8w ago | Insider Cluster | $110.77 $111.62 | ▲ +0.77% | ▲ +1.16% | $116.49 (+5.16%) |
Aug 5, 2026 8w ago | Insider Cluster | $107.95 $112.80 | ▲ +4.49% | ▲ +3.89% | $116.49 (+7.91%) |
Jul 23, 2026 10w ago | Court Ruling | $96.66 $121.05 | ▲ +25.23% | ▲ +21.92% | $116.49 (+20.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access